Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KV Pharmaceuticals

Executive Summary

Agreement with "largest marketer of OTC drugs in Japan" exchanges Japanese rights to KV/24 line of long-acting cough/cold products for cash payments, royalties and manufacturing revenues. Certain KV/24 products await FDA approval for the U.S. market. Japanese firm has also purchased 200,000 shares of a recently concluded $19.6 mil., or 784,100 share, private placement of 7% convertible preferred stock through Nomura Securities.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel